bearish
Teladoc Health Inc (TDOC US): Q2 Revenue Beat Expectations; Here Is Why the Stock Toppled
298 Views28 Jul 2022 21:02
SUMMARY
- Teladoc Health, Inc. (TDOC US) reported mixed Q2 results, with revenue and adjusted EBITDA coming in above the midpoint of guidance range. However, EPS came significantly below consensus and guidance.
- Teladoc has already took $9.8 billion hit from impairment charge in H1 2022. Moreover, the company now expects results to be toward the lower end of already reduced guidance range.
- Since publishing Q1 results in April, the stock plummeted 23% in three months. From its peak in February 2021, the stock is now down 85%. No immediate recovery is expected.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
- Teladoc Health Inc (TDOC US): Q2 Revenue Beat Expectations; Here Is Why the Stock Toppled28 Jul 2022
- Teladoc Health Inc (TDOC US): 1Q22 Results Review- Revenue Missed, 2022 Guidance Reduced28 Apr 2022
- Teladoc (TDOC US): Membership Add and Expanding Product Penetration to Drive 25–30% Top Line Growth19 Jan 2022
x